Key result
LPAR5 inhibition rescues anti-PD1-induced myocarditis by blocking LPA-driven cardiomyocyte pyroptosis in preclinical models.
Why the study?
Immune checkpoint inhibitor-associated myocarditis (ICIAM) limits the clinical utility of PD1 inhibitors. This study explored the link between inflammatory metabolic reprogramming-induced AGPAT2 and lysophosphatidic acid (LPA) imbalance and ICIAM to identify diagnostic and treatment targets.
Does inflammatory metabolic reprogramming of the AGPAT2-LPA-LPAR5 axis mediate pyroptotic myocardial damage and immune checkpoint inhibitor-associated myocarditis?
Does inflammatory metabolic reprogramming of the AGPAT2-LPA-LPAR5 axis mediate pyroptotic myocardial damage and immune checkpoint inhibitor-associated myocarditis?
Identifies the AGPAT2-LPA-LPAR5-pyroptosis axis as a key pathogenic mechanism in ICI-associated myocarditis, proposing serum LPA as a diagnostic biomarker and LPAR5 inhibition as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
LPAR5 inhibition attenuates ICI-myocarditis in mice; leaves open clinical translation and LPA biomarker utility in patients.
Objectives: Immune checkpoint inhibitors (ICIs), especially programmed cell death protein-1 (PD1) inhibitors, are effective onco-therapeutic agents. However, ICI-associated myocarditis (ICIAM) greatly limits their clinical utility. Imbalance between 1-acylglycerol-3-phosphate O-acyltransferases (AGPAT2) and lysophosphatidic acid (LPA) induced by inflammatory metabolic reprogramming (IMRP) might cause cardiovascular injury. This study aims to explore the link between AGPAT2 pathway and ICIAM as well as identifies diagnosis and treatment targets of ICIAM. Methods: ICIAM model was established by injecting anti-PD1 (αPD1) in wild-type (WT) and AGPAT2 heterozygous knockout (AGPAT2+/-) mice. The pathogenic and regulating mechanisms of AGPAT2-LPA and its downstream signaling were examined in vitro and in vivo. A tumor-patient cohort was enrolled to observe the association between serum LPA and risk of ICIAM. Results: In the αPD1-induced ICIAM model, myocardial IMRP occurred due to upstream immunity disorder, leading to downstream AGPAT2 degradation via lysosomal pathway and subsequent LPA accumulation. Knockout of AGPAT2 gene also promoted LPA accumulation. The accumulated LPA, by binding to its dominant receptor subtype 5 (LPAR5), triggered pyroptotic myocardial damage and resultant ICIAM. LPAR5 knockdown with siRNA or inhibition with TCLPA5-4 played the most significant rescue effect on myocardial pyroptosis, while stimulating LPAR5 with overdose LPA significantly increased myocardial pyroptosis. In ICI-treated patients, elevated serum LPA was associated with increased risk of ICIAM. Conclusions: IMRP-triggered dysfunction of AGPAT2-LPA-LPAR5-pyroptosis axis is involved in pathogenesis of ICIAM. Several elements in this axis may be the promising targets in diagnosis (LPA as a biomarker) and treatment (LPA or LPAR5 as therapeutics) of ICIAM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Immune checkpoint inhibitor-associated myocarditis (ICIAM). Anti-PD1 injection, AGPAT2 knockout, and LPAR5 modulation (siRNA knockdown, TCLPA5-4 inhibition, or overdose LPA stimulation) vs. Wild-type control / unstimulated control was evaluated on Pyroptotic myocardial damage and ICI-associated myocarditis (ICIAM). Anti-PD1-induced AGPAT2 degradation and LPA accumulation triggered ICI-associated myocarditis via LPAR5-mediated pyroptosis, while LPAR5 inhibition with TCLPA5-4 or siRNA rescued myocardial damage.
Synapse has enriched 10 related papers. Consider them for comparative context: